Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-14
2005-06-14
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211150, C514S217050, C514S218000
Reexamination Certificate
active
06906057
ABSTRACT:
Methods for modulating the activity of the mammalian FXR receptor. The methods include methods of treating a hyper- or hypocholesterolemic mammal comprising contacting the mammal with synthetic compounds having FXR receptor activity.
REFERENCES:
patent: 5053523 (1991-10-01), Chandraratna
patent: 5278318 (1994-01-01), Chandraratna
patent: 5324744 (1994-06-01), Chandraratna
patent: 5346895 (1994-09-01), Chandraratna
patent: 5348972 (1994-09-01), Chandraratna
patent: 5348975 (1994-09-01), Chandraratna
patent: 5407937 (1995-04-01), Chandraratna
patent: 5663347 (1997-09-01), Chandraratna
patent: 5776699 (1998-07-01), Klein et al.
patent: 5808083 (1998-09-01), Johnson et al.
patent: 5877207 (1999-03-01), Klein et al.
patent: WO 00/40965 (2000-07-01), None
Evans et al, “The Steroid and Thyroid Hormone Receptor Superfamily” Science vol. 240: 889-895 (May 1988).
Mangelsdorf et al, The Retinoid Receptors in The Retinoids: Biology, Chemistry, and Medicine Ch.8 (Sporn et al, eds. 2d ed, Raven Press Ltd. 1994).
Nagpal et al, “Retinoids as Anti-Cancer Agents”, Current Pharm. Design 2:295-316 (1996).
Foreman et al, “Identification of a Nuclear Receptor That is Activated by Farnesol Metabolites”, Cell vol. 81: 687-693 (1995).
Meigs et al, “Regulation of 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Degradation by the Nonsterol Mevalonate Metabolite Farnesol in Vivo*”, J. Biol. Chem. vol. 271: 7916-7922 (1996).
Chiang, “Regulation of Bile Acid Synthesis”, Front. Biosci. 3: d176-193 (Feb. 1998).
Wang et al, “Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR”, Molecular Cell vol. 3: 543-553 (May 1999).
Seed, “An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologuous to its receptor CD2”, Nature vol. 329: 840-842 (Oct. 1987).
Umesono et al, “Direct Repeats as Selective Response Elements for the Thyroid Hormone, Retinoic Acid, and Vitamin D3Receptors”, vol. Cell 65: 1255-1266 (1991).
Sadowski et al, “A vector for expressin GAL4(1—1470 fusions in mammalian cells”, Nucleic Acids Research, vol. 17, No. 18: 7539 (1989).
Forman et al, “15-Deoxy-12, 14-Prostoglandin J2Is a Ligand for the Adipocyte Determination Factor PPARγ”, Cell vol. 83:803-812 (1995).
de Wet et al, “Firefly Luciferase Gene: Structure and Expression in Mammalian Cells”, Mol. Cell Biol. vol. 7, No. 2, 725-737 (Feb. 1987).
Heyman et al, “9-Cis Retinoic Acid Is a High Affinity Ligand for the Retinoid X Receptor”, Cell vol. 68: 397-406 (1992).
Corey et al, “Useful Procedures for the Oxidation of Alcohols Involving Pyridinium Dichromate in Aprotic Media” Tet. Lett., No. 5, 399-402, 1979.
Omura et al, “Oxidation of Alcohols by “Activated” Dimethyl Sulfoxide. A Preparative, Steric and Mechanistic Study”, Tetrahedron vol. 34, 1651-1660, (1978).
Beard Richard L.
Chandraratna Roshantha A.
Forman Barry M.
Allergan Inc.
City of Hope National Medical Center
Hamilton Brook Smith & Reynolds P.C.
Hui San-ming
LandOfFree
Methods for modulating FXR receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating FXR receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating FXR receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3504379